Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
butaminofen
- Development stage
- Unknown
- Lead developer
- Research Institute for Physical and Chemical Problems of the Belarusian State University
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Butaminofen is a small molecule antiviral agent developed by the Research Institute for Physical Chemical Problems of the Belarusian State University (RI PCP BSU). It is primarily indicated for the topical treatment of acute and recurrent infections caused by Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), including herpetic lesions of the skin and mucous membranes. Formulated as a 2% ointment, butaminofen exerts its therapeutic effect by inhibiting viral replication, thereby reducing the duration of viral shedding and accelerating the healing of lesions. It is an original pharmaceutical substance approved for use in Belarus and represents a non-nucleoside approach to managing herpetic infections.
- Brand names
- ButaminofenovayaButaminofenovaya Ointment 2%
- Other names
- butaminofenButaminofenumБутаминофен
Beyond the preview
Go deeper on butaminofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on butaminofen.